We're proud to announce DCVC Bio III: $400 million in fresh capital to support great scientific teams with boundary-pushing ideas for curing disease, extending health-spans, enabling healthy food at lower cost and climate impact, and more!
bit.ly/3ZRmdpo
Exciting progress for Syntax Bio: a research and development collaboration with @MayoClinic focused on advancing stem cell-derived pancreatic cell therapies for type 1 diabetes š
businesswire.com/news/home/2ā¦
ššØš§šÆšš«š šš§šš š šØš«š®š¦: Chicago based Grove Biopharma has engineered a technology, Bionic Biologics, that it hopes will give its therapies the versatility of biologics in a small molecule format. #ConvergenceForum
We are proud to announce that STX-0712, our Phase 1 CCR2-CyTAC⢠program in development for patients with resistant/refractory #CMML, has received FDA Fast Track designation. For more information, see our press release: cdn.prod.website-files.com/6ā¦
Gene therapy is moving from promise to precision.
Latus Bio added a $43M Series A extension from @8vc, @DCVCBio, and Hatch BioFund, bringing the round to $97M. P. Peter Ghoroghchian is building an AI-enabled platform focused on precision AAV delivery for neurological disease.
The next biotech edge will come from pairing better vectors with better computational judgment.
At @DCVCBio, we see aĀ need for aĀ massive reinĀvestĀment in the search for drugs that safely lessen anxiety, including existing compounds that have been shelved by big pharma companies.
More on our thinking in š§µ
RNA- and DNA-based treatments (gene/cell therapy) have high upfront costs but are curative and more economical than chronic care. Regulators should work with insurers and manufacturers to cover costs and introduce new business models, like gradual payment plans.
More in š§µ
Weāre seeing aĀ new wave of gene therapy companies developing exquisitely customized viral vectors other advanced techniques that can deliver therapeutic genes to the body with far more specificity and at much lower doses and cost than before. š
dcvc.com/news-insights/deep-ā¦
In the @WSJ, our friend @crisman_ryan, co-founder of @UmojaBiopharma, offers a beautiful example of basic research meandering through labs over decades, then providing learnings that help us reset the immune systems of leukemia autoimmune patients:
on.wsj.com/4aKcN4P
Orca-T, our investigational allogeneic T-cell immunotherapy, is a finalist in the Biotech Innovation category of the Fierce Innovation Awards: Life Sciences Edition 2025!
This award recognizes the companies and innovations pushing science forward to transform the field of life sciences. We're proud of the work we do on behalf of patients, and honored to be included.
To learn more: orcabio.com/#FierceLifeSciencesAwards and #FierceInnovationAwards
Today, Orca Bio announced the FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T to treat hematological malignancies.
Read more in the press release: bit.ly/4q1Uzkw#celltherapy#hematology#oncology
How is Grove Biopharma archiĀtecting its way around traditional drugĀ limits? Learn from @DCVCBio principal Dr. Emily Park and managing partner @2kstead š (link in š§µ)
Augmented RNA reality is emerging! @creyonbio has the ability to programĀmatĀiĀcally engineer knowably safe and effective siRNAs, ASOs, and other oligo therapies to unlock aĀ huge range of therapeutic advancesš
dcvc.com/news-insights/creyoā¦
Creyon Bio names Serge Messerlian as CEO and appoints Kiersten Stead, PhD, to the Board. With revitalized leadership & AI-powered oligo tech, we're advancing therapies in CNS, neuromuscular, & immunologic diseases. creyonbio.com/latest-news/#BiotechNews#AIinHealthcare